The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma.
The purpose of this article is to review the clinical utility of FDG and FDG PET/CT imaging in lymphoma and melanoma. A review of the important articles supporting the use of FDG PET imaging in the staging, restaging, and monitoring of response to therapy in lymphoma and melanoma is provided. The intent is to give the nuclear medicine physician and or radiologist the perspective of what may be important clinically to make FDG PET imaging an integral part of the workup of lymphoma and melanoma patients. Specific clinical scenarios and uptake patterns that are unique for lymphoma and melanoma are discussed to ensure relevant and proper interpretation of the FDG PET scans. FDG PET scanning in summary is a useful imaging modality in the staging, restaging, and response evaluation of patients with lymphoma and melanoma.
Macapinlac
Homer A
HA
Division of Diagnostic Imaging, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA. hmacapinlac@di.mdacc.tmc.edu
D001921:Brain / Q000000981:diagnostic imaging / Q000473:pathology; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis* / Q000000981:diagnostic imaging; D008545:Melanoma / Q000175:diagnosis* / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography; D014055:Tomography, Emission-Computed
D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18